Corvus Pharmaceuticals, Inc.

NasdaqGM:CRVS Stock Report

Market Cap: US$320.6m

Corvus Pharmaceuticals Management

Management criteria checks 3/4

Corvus Pharmaceuticals' CEO is Rick Miller, appointed in Feb 2014, has a tenure of 10.83 years. total yearly compensation is $1.32M, comprised of 8.3% salary and 91.7% bonuses, including company stock and options. directly owns 2.75% of the company’s shares, worth $8.81M. The average tenure of the management team and the board of directors is 5 years and 9.5 years respectively.

Key information

Rick Miller

Chief executive officer

US$1.3m

Total compensation

CEO salary percentage8.3%
CEO tenure10.8yrs
CEO ownership2.7%
Management average tenure5yrs
Board average tenure9.5yrs

Recent management updates

Recent updates

Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting

Dec 18

Corvus Pharmaceuticals: The Market Likes The Story

Nov 13

Corvus Pharmaceuticals: Soquelitinib's High Stakes In PTCL Therapy

Sep 02

Will Corvus Pharmaceuticals (NASDAQ:CRVS) Spend Its Cash Wisely?

Mar 06
Will Corvus Pharmaceuticals (NASDAQ:CRVS) Spend Its Cash Wisely?

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Oct 23
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth?

May 16
Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth?

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Dec 05
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Corvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in China

Sep 26

We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate

Aug 14
We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate

Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth

Apr 05
Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth

We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely

Dec 15
We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely

Checking In On Corvus Pharmaceuticals

Dec 10

Corvus: Surging On AstraZeneca CD73 Success With Key Data Readout Looming

Sep 22

We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth

Aug 26
We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth

Corvus Pharmaceuticals initiated buy at Cantor with a Street-high target

May 27

Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?

May 08
Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?

The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More Shares

Feb 19
The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More Shares

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Feb 07
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Here's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks Like

Dec 16
Here's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks Like

Corvus Pharmaceuticals EPS misses by $0.06

Oct 29

CEO Compensation Analysis

How has Rick Miller's remuneration changed compared to Corvus Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$57m

Jun 30 2024n/an/a

-US$23m

Mar 31 2024n/an/a

-US$25m

Dec 31 2023US$1mUS$110k

-US$27m

Sep 30 2023n/an/a

-US$30m

Jun 30 2023n/an/a

-US$39m

Mar 31 2023n/an/a

-US$41m

Dec 31 2022US$524kUS$300k

-US$41m

Sep 30 2022n/an/a

-US$41m

Jun 30 2022n/an/a

-US$37m

Mar 31 2022n/an/a

-US$40m

Dec 31 2021US$905kUS$300k

-US$43m

Sep 30 2021n/an/a

-US$7m

Jun 30 2021n/an/a

-US$6m

Mar 31 2021n/an/a

-US$5m

Dec 31 2020US$1mUS$300k

-US$6m

Sep 30 2020n/an/a

-US$44m

Jun 30 2020n/an/a

-US$46m

Mar 31 2020n/an/a

-US$48m

Dec 31 2019US$1mUS$300k

-US$47m

Sep 30 2019n/an/a

-US$46m

Jun 30 2019n/an/a

-US$46m

Mar 31 2019n/an/a

-US$44m

Dec 31 2018US$1mUS$300k

-US$47m

Sep 30 2018n/an/a

-US$48m

Jun 30 2018n/an/a

-US$51m

Mar 31 2018n/an/a

-US$54m

Dec 31 2017US$1mUS$302k

-US$56m

Compensation vs Market: Rick's total compensation ($USD1.32M) is below average for companies of similar size in the US market ($USD2.16M).

Compensation vs Earnings: Rick's compensation has increased whilst the company is unprofitable.

CEO

Rick Miller (73 yo)

10.8yrs

Tenure

US$1,321,351

Compensation

Dr. Richard A. Miller, also known as Rick, M.D., serves as Director of BrainScope Company Inc. since September 2023. He is a Co-Founder of Corvus Pharmaceuticals, Inc. and has been its Chief Executive Offi...

Leadership Team

NamePositionTenureCompensationOwnership
Richard Miller
Co-Founder10.8yrsUS$1.32m2.75%
$ 8.8m
Peter Thompson
Co-Founder & Independent Directorno dataUS$95.35kno data
Leiv Lea
Chief Financial Officer10.1yrsUS$660.76k0.44%
$ 1.4m
William Jones
Senior Vice President of Pharmaceutical Development5yrsUS$616.26k0.24%
$ 767.3k
James Rosenbaum
Senior Vice President of Research2.4yrsno datano data
Jeffrey Arcara
Chief Business Officerless than a yearno datano data

5.0yrs

Average Tenure

67yo

Average Age

Experienced Management: CRVS's management team is seasoned and experienced (5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Richard Miller
Co-Founder10.9yrsUS$1.32m2.75%
$ 8.8m
Peter Thompson
Co-Founder & Independent Director10.1yrsUS$95.35kno data
Elisha Gould
Independent Director10.1yrsUS$101.35kno data
Linda Grais
Independent Director5.9yrsUS$97.35k0.016%
$ 49.9k
Ian T. Clark
Independent Director7.9yrsUS$93.35kno data
Scott William Morrison
Independent Director9yrsUS$109.35kno data

9.5yrs

Average Tenure

66.5yo

Average Age

Experienced Board: CRVS's board of directors are considered experienced (9.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 07:21
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Corvus Pharmaceuticals, Inc. is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dane LeoneBTIG
Li Wang WatsekCantor Fitzgerald & Co.
Vamil DivanCredit Suisse